摘要
目的评价利妥昔单抗治疗复发难治性免疫相关性血小板减少症的临床疗效及患者的不良反应。方法 2例ITP患者均明确诊断为ITP,经糖皮质激素、细胞因子等治疗缓解后再次复发,在行利妥昔单抗100 mg/m2,静脉滴注,每周1次,共用4周为1个疗程。结果 1例患者因治疗时间长,3周后停药,门诊监测血常规提示患者于2个月后血小板达到75×109/L,1年后患者再次复发。1例患者完成4周治疗,门诊监测血常规是血小板恢复正常,监测至今约1年,患者未复发。结论利妥昔单抗是治疗复发难治性免疫相关性血小板减少症的有效方法。
Objective To evaluate rituxan treatment of recurrence of refractory correlation immune thrombocytopenia in patients with the clinical curative effect and adverse reactions. Methods 2 patients with ITP were clearly diagnosed with ITP, glucocorticoid, cytokines and other treatment to ease after the relapse again, good rituxan 100 mg/m2, intravenous drip, 1 times a week, and Shared 4 weeks for a course of treatment. Results 1 case of patients because of long treatment time, 3 weeks after drug withdrawal, outpatient service monitoring and routine blood platelet after the patients in the two months of 75×10^9/L, 1 years patients relapse again. 1 patients completed 4 weeks of treatment, outpatient service monitoring and routine blood platelet is back to normal, monitoring to about 1 year, patients without recurrence. Conclusion Recurrence of rituxan treatment is the effective method of refractory correlation immune thrombocytopenia.
出处
《中国卫生标准管理》
2015年第4期101-102,共2页
China Health Standard Management
